Critical Review of the Ankle Brachial Index

Tahir H. Khan1,7, Falahat A. Farooqui2 and Khusrow Niazi3

1Hospitalist / Instructor of Medicine, Emory University Dept of Medicine, Emory Crawford Long Hospital, 550 Peachtree St, MOT 6th Fl Rm 4307, Atlanta, GA 30308, USA; 2Dept of Medicine / Div of Cardiology, Emory University, 550 Peachtree St, MOT 6th Floor, Atlanta GA 30308, USA; 3Emory University School of Medicine, Director of Peripheral Intervention, Emory Crawford Long Hospital, 550 Peachtree St, MOT 6th Fl Rm 4307, Atlanta, GA 30308, USA

Abstract: Ankle brachial index (ABI) has been utilized in the management of peripheral arterial disease (PAD). ABI is a surrogate marker of atherosclerosis and recent studies indicate its utility as a predictor of future cardiovascular disease and all-cause mortality. Even so, this critical test is underutilized. The purpose of this review is to summarize available evidence associated with ABI methodology variances, ABI usage in the treatment of PAD, and ABI efficacy in predicting cardiovascular disease. This review further evaluates how ABI is used in the prognosis and follow-up of lower extremity arterial disease. We reviewed the most current American College of Cardiology guidelines for the management of PAD, the Trans Atlantic Intersociety Consensus (TASC) working group recommendations, and searched the Medline for the following words: ankle brachial index, ABI sensitivity and specificity, and peripheral arterial disease.

The ABI is a simple, noninvasive clinical test that should not only be applied to diagnose PAD, but also to provide important prognostic information about future cardiovascular events. Although the ABI has been employed in clinical practice for some time, our review of various studies reveals a lack of standardization regarding both the method of measuring ABI and the cutoff point for abnormal ABI. It is extremely important that we understand all aspects of this crucial test, as it is now being recommended as part of a patient’s routine health risk assessment.

Key Words: Peripheral arterial disease, Ankle Brachial index, ABI Sensitivity and Specificity, Atherosclerosis, Cardiovascular morbidity and mortality.

INTRODUCTION

Peripheral arterial disease (PAD) of the lower extremities is a common disease affecting approximately 12 million people in the United States [1]. Atherosclerosis is the major cause of PAD of lower extremities [2]. The prevalence of PAD varies based on the population surveyed and the methodology of computing the ankle-brachial index (ABI) [3-5]. The ABI is the preferred initial screening test to help diagnose and grade the obstruction of peripheral arterial disease (PAD) in the legs. Interval ABI results are used to monitor the efficacy of revascularization procedures of lower extremities. Additional uses of ABI include predicting the prognosis regarding the limb salvage, wound healing and future cardiovascular related morbidity and mortality [6].

HISTORICAL PERSPECTIVE

Arterial measurements in lower extremities were first described by Naumann in 1930 [7]. In 1950, Winsor was first to use ABI measurements in patients with peripheral arterial disease [8].

METHODS OF MEASURING ANKLE BRACHIAL INDEX

The measurement of the ABI involves recording the systolic pressures in the brachial artery at each elbow and systolic pressures in the posterior tibial and the dorsalis pedis arteries at each ankle. The result is reported as a ratio of the ankle systolic pressure in the numerator, over the higher brachial pressure in the denominator. The ABI is calculated for each leg separately, and the lower of the two values is taken as a result for the patient. Numerous methods of calculating the ABI have been described based with variances in the numerator taken in the ABI equation:

a) The current method recommended by the ACC/AHA involves using the higher of the two ankle systolic arterial pressures, termed high ankle pressure (HAP) (Fig. 1) as the numerator in the ABI equation [2,6,9-12].

b) A second method reported in the literature uses the lower of the two ankle systolic arterial pressures, termed low ankle pressure (LAP) as the numerator when calculating the ABI [5,13,14].

c) A calculation applied in some epidemiological studies uses the average of the two ankle systolic pressures as the numerator in the ABI equation [15,16].

d) A few studies have used the posterior tibial artery systolic pressure to calculate ABI [17,18].

INTERPRETATION OF ABI RESULTS

The patient is diagnosed with PAD when the ABI is \( \leq 0.9 \) [2,19]. PAD is graded as mild to moderate if the ABI is between 0.4 and 0.9, and an ABI less than 0.40 is suggestive of severe PAD [19]. An ABI value greater than 1.3 is also considered abnormal, suggestive of non-compressible vessels.

CORRELATION OF ABI WITH LOWER EXTREMITY FUNCTION AND OUTCOMES

Patients with mild to moderate PAD are likely to experience lower extremity pain with exercise (claudication). Pa-
Patients with ABI less or equal to 0.5 are likely to have lower extremity pain while resting [20]. Criqui et al. reported that the incidence of claudication (applying Rose criteria) was 49% in patients with ABI < 0.6 compared to 34% in patients with ABI between 0.6 and < 0.9 [21].

Several specific ABI values indicate evidence of correlation with the leg function in multiple studies. In a study of 865 women aged 65 and older, McDermott et al. discovered that subjects with ABI < 0.6 were at higher risk of having impaired walking abilities [13]. In an earlier study McDermott et al. [22] reported that among patients with PAD, decreases in ABI values are associated with decreases in six minute walk distance, maximum walking speed, and walking endurance. Each increase of 0.4 in the ABI was associated with an increase in the six minute walk distance and usual and maximal walking speed.

An ABI <0.4 increases the risk of limb loss, gangrene, ulceration and delayed wound healing [6,23]. However, an absolute ankle systolic pressure less than 60 mmHg, rather than the ABI value, has been found to correlate better in terms of viability of the lower extremities in PAD [2,24].

SENSITIVITY AND SPECIFICITY OF THE ABI IN THE DIAGNOSIS OF PAD

Numerous studies have reported that the ABI, when compared to angiography, has a sensitivity of more than 90% and a specificity of more than 95% in diagnosing 50% stenosis of the lower extremity arteries [6,11,12,16,17,25,26]. However, Schroder et al. recently reported that the HAP ABI had a sensitivity of 68% and a specificity of 99% [27]. The authors reported the LAP ABI sensitivity and specificity to be 89 and 93% respectively. Niazi et al. reported that the HAP ABI had a sensitivity of 69% with a specificity of 83%. The sensitivity and specificity of the LAP ABI was 84% and 64% respectively [28].

Feigelson et al. [29] evaluated the sensitivity of an ABI < 0.8 to be 39% within the entire cohort and 70% in patients with PAD (This study is reported by ACC/AHA guidelines that ABI has a sensitivity of 89% in diagnosing PAD). Lijmer et al. has reported that an ABI value of 0.91 had a sensitivity of 79% and a specificity of 96% to detect 50% or more stenosis of lower extremity arteries defined on angi-
role [30]. Angiograms of the lower extremities were available for only 53 patients (12% of the total patients in study). Stoffers et al. applied ROC analysis and reported the sensitivity and specificity for ABI < 0.97 to be 79% and 82% respectively [31]. When two vascular technicians using ultrasound technology interpreted the ankle arterial pulse waveforms as “pathologic”, the diagnosis of PAD was determined. No angiographic confirmation for the diagnosis of PAD was provided.

Based on the evaluated studies, we find that the lower ankle pressure ABI has better sensitivity in diagnosing PAD. Additionally, the context in which few studies [24,32-34] are reported (that ABI has been shown to be > 90% sensitive and > 95% specific to diagnose 50% stenosis of lower arteries) is inaccurate. Carter and Yao [32,33] only concluded that ABI was low in patients with PAD without providing any ABI sensitivities. Ouriel did report in his two studies [23,34] that ABI < 0.97 has a sensitivity of more than 97% and specificity of more than 100% respectively in diagnosing PAD. Nevertheless, the lack of the authors definition of PAD in terms of diameter stenosis of the arteries weakens the validation of their findings.

ROLE OF THE ABI IN THE FOLLOW UP OF PAD PATIENTS AFTER LOWER EXTREMITY INTERVENTION

Mclafferty et al. reported the sensitivity and specificity of ABI to detect the progression of lower extremity arterial disease after surgical intervention [35]. One hundred fourteen patients (193 Limbs) were followed for a mean of 33 years. A baseline ABI was established for each patient, followed by another ABI within a week of the revascularization procedure. Progression of the PAD was documented with arterial duplex scanning or arteriography of the lower extremities if clinically indicated. Disease progression was only monitored in native arteries and not in the bypass grafts. The authors reported that a drop of the ABI more than 0.15 carried a sensitivity of 41% and a specificity of 84% to detect the progression of lower extremity arterial disease.

Decrnis et al. tested the sensitivity and specificity of ABI in patients who had undergone angioplasty of the superficial femoral artery stenosis [36]. ABI were performed postoperative day one, three, six and twelve months after the procedure. Follow up angiograms of the lower extremities were performed one year after angioplasty. A total of 116 patients were enrolled in the study. (Angiographic definition of restenosis was progression of post PTA 50% stenosis to more than 70% at follow up angiogram or an increase in the stenosis severity to 10% or more of predilation obstruction.) For an ABI drop of 0.10 the sensitivity and specificity were 72% and 82% respectively in predicting restenosis using their criteria. An ABI drop of 0.15 had a sensitivity and specificity of 66% and 100% respectively for restenosis. In predicting the patency of the post PTA vessel, an improvement of ABI of 0.10 post PTA had sensitivity and specificity of 79% and 92%. ABI improvement of 0.15 post PTA had sensitivity and specificity of 67% and 100% respectively for patency of post PTA artery.

ABNORMAL ABI AS MARKER OF ATHEROSCLEROSIS AND PREDICTOR OF FUTURE CARDIOVASCULAR MORBIDITY AND MORTALITY

The unique role that ABI plays as a marker of atherosclerosis is clear by its correlation with cardiovascular disease (CVD) in multiple population based studies [9-18]. The measurement of ABI has been recommended as part of risk assessment and primary prevention of CVD in asymptomatic individuals who have intermediate risk factors for CVD [37,38]. There is consensus that an abnormal ABI in an otherwise asymptomatic individual would categorize him in the high risk category for future CVD. The American Diabetes Association recommends routinely screening all patients with diabetes above age 50 and in all diabetics with risk factors (e.g. smoking, hyperlipidemia etc) for PAD under age 50 [39].

1) Cardiovascular Disease (CVD) and Mortality

Numerous epidemiologic studies have reported up to four fold increased rates of cardiovascular disease and mortality with abnormal ABI [9-18,40-49]. Findings of some of these are summarized in Table 1.

Vogt et al. reported that the mortality rates from atherosclerotic heart disease doubled (RR 2.0 95% CI 1.4-2.9) with each 0.5 units drop in the ABI [16]. The ten year mortality rates of CVD in patients with an ABI < 0.5 was 37%, compared to 27% in patients with ABI values ranging between 0.5-0.7, 22% in patients with ABI 0.7-0.9 and 17% in patients with ABI values >0.9 (P=0.0039). Relative risk for all cause mortality was higher (1.95, 95% CI 1.42-2.68) in subjects with ABI < 0.5 compared to subjects with ABI values ranging between 0.51-0.7 (RR 1.59, 95% CI 1.18-2.15).

O’Hare et al. investigated the rates of cardiovascular disease and mortality across different levels of ABI [40]. The cohort included 5748 subjects, their mean age was 73 years, and the mean follow-up was 11 years. The study found that subjects with an ABI < 0.6 was consistently associated with increased CV mortality (hazard ratio [HR] 2.13 95% CI 1.49-30.5), all cause mortality (HR 1.82,95% CI 1.42-2.32) and cardiovascular events(HR 1.60,95% CI 1.09-2.34) compared to participants with ABI 1.10-1.20. In the Framingham Offspring study the prevalence of CAD was 30% in patients with an ABI < 0.9 compared to 10% in subjects with ABI >1.0 (P 0.001) [41]. Among the participants of the HOPE trial, the percent rates of CV disease, CV death and all cause mortality in subjects with an ABI >0.9 were 10.1,5.3 and 8.8 respectively, compared to 13.7, 8.6,12.8 in the ABI group 0.6-0.9, and 13.4, 9.4 and 14.7 in the ABI group < 0.6 respectively [42].

2) Risk for Stroke / Transient Ischemic Attack (TIA)

Zheng et al. reported that the risk of Stroke /TIA for men with ABI < 0.9 was four times (Odds Ratio 4.2 -4.9, 95% CI 1.8-9.5) than in those with an ABI >0.9 [43]. In the Framingham study, the risk of stroke/ TIA was two fold (Hazards ratio 2.0, 95% CI 1.1-3.7) among participants with an ABI< 0.9 [15]. In the Framingham offspring study the prevalence of stoke was 9% in men with ABI< 0.9 compared...
Current Cardiology Reviews, 2008, Vol. 4, No. 2

Khan et al.

In the Cardiovascular Health Study, patients with ABI <0.8 had twice the rates of stroke/TIA [44]. Similarly, Leng et al. reported that subjects with an ABI <0.9 had increased risk of stroke (RR 1.98, 95% CI 1.05-3.77) [45].

In a meta analysis of nine studies Doobay reported the predictive value of ABI in predicting future cardiovascular events [46]. The authors reported that an ABI less than 0.9 has a sensitivity and specificity of 16.55 and 92.7% for CAD (likelihood ratio 2.53), 16.0% and 92.2% for stroke (likelihood ratio 2.45) and 41.0% and 87.9% for cardiovascular mortality (likelihood ratio 5.61), respectively.

Heald et al. performed a systematic review of 11 published studies with a combined number of 44590 subjects [47]. The authors reported that ABI < 0.9 was associated with increased all cause mortality (RR 2.35, P< 0.001), cardiovascular and cerebrovascular mortality (RR 2.34, P =0.002), fatal and non-fatal coronary heart disease (RR 2.13, P= 0.003) and fatal and non-fatal stroke (RR 1.86, P=0.07).

An ABI < 0.9 identifies subjects with increased future cardiovascular morbidity and mortality. However, across the range of ABI a value < 0.6 has been found with increased CV events (Table 1).

3) Abnormal ABI as Predictor of Morbidity and Mortality in Post-Coronary Artery Bypass Graft Patients

Abnormal ABI has been found as prognostic indicator for survival and complications among patients undergoing coronary artery bypass surgery. Aboyans V et al. studied the role of abnormal ABI as a marker for long term prognosis in the post coronary artery bypass graft patients (CABG) [48]. The mean age of the patients was 69 years with a follow-up of 4.4 years. Patients with clinical PAD (defined as history of vascular surgery and/or history of intermittent claudication) and sub clinical PAD (defined as ABI<0.85) had three fold excess risk of primary end points (composite of cardiovascular death, non-fatal acute coronary syndrome, non-fatal stroke, TIA and coronary or peripheral revascularization) compared to patients without PAD after CABG. Risk of acute coronary syndrome was more than two times (HR 2.12 to 2.35) in patients with clinical and sub clinical PAD.

Burek et al. studied the five year mortality rates in Post CABG/ Coronary PTCA patients. The five year mortality

| Study          | No Study Subjects | ABI   | Effect Measure | CVD   | CVD Mortality | All Cause Mortality | Stroke/TIA |
|---------------|-------------------|-------|----------------|-------|---------------|---------------------|------------|
| Diehm et al.  | 12                | 6880  | <0.9           | Odds Ratio | 1.53          | N/A                 | N/A        | 1.77        |
| Vogt et al.   | 16                | 1930  | >0.9           | Relative Risk | N/A          | Relative Risk  | 1.0        | No Significant association |
| O'Hare et al. | 40                | 5748  | 0.91-1.0       | Hazard Ratio | 1.37          | 1.60               | 1.40       | Included in CVD. |
| Ostergen et al. | 42              | 8986  | >0.9           | Four year Clinical outcomes (Percent rates). | 10.1          | 5.3                | 8.8        | 3.5         |
| Zheng et al.  | 43                | 15106 | <0.9           | Odds Ratio | 4.5           | N/A                 | N/A        | 4.3 (P<.001) |
| Leng et al.   | 45                | 1592  | 1.0-0.9        | Five Year Incidence | 5%           | 6%                 | 11%        | 3%          |
|               |                   |       | 0.9-0.71       |               | 7%            | 8%                 | 16%        | 3%          |
|               |                   |       | <0.7           |               | 9%            | 21%                | 34%        | 3%          |
|               |                   |       |                |               | P<0.001       | P<0.001            | P<.001     | P<0.020     |

N/A: Data not provided; CVD: Cardiovascular Disease; TIA: Transient Ischemic attack.

to 2 % in men with ABI > 1.0 (0.001) [41]. In the Cardiovascular Health Study, patients with ABI <0.8 had twice the rates of stroke/TIA [44]. Similarly, Leng et al. reported that subjects with an ABI <0.9 had increased risk of stroke(RR 1.98, 95% CI 1.05-3.77) [45].

In a meta analysis of nine studies Doobay reported the predictive value of ABI in predicting future cardiovascular events [46]. The authors reported that an ABI less than 0.9 has a sensitivity and specificity of 16.55 and 92.7% for CAD (likelihood ratio 2.53), 16.0% and 92.2% for stroke (likelihood ratio 2.45) and 41.0% and 87.9% for cardiovascular mortality (likelihood ratio 5.61), respectively.

Heald et al. performed a systematic review of 11 published studies with a combined number of 44590 subjects [47]. The authors reported that ABI < 0.9 was associated with increased all cause mortality (RR 2.35, P< 0.001), cardiovascular and cerebrovascular mortality (RR 2.34, P =0.002), fatal and non-fatal coronary heart disease (RR 2.13, P= 0.003) and fatal and non-fatal stroke (RR 1.86, P=0.07).

An ABI < 0.9 identifies subjects with increased future cardiovascular morbidity and mortality. However, across the range of ABI a value < 0.6 has been found with increased CV events (Table 1).

Table 1. Cardiovascular, Stroke / TIA and All Cause Mortality Across Range of ABI in Published Studies
rate was 14% in patients with ABI < 0.9 compared to 3% in patients with ABI > 0.9 (RR 4.9 95% CI 1.8-13.4, P 0.001) [49]. The investigators reported that abnormal ABI< 0.9 was a strong predictor of mortality among patients with multivessel CAD.

CONCLUSION

We conclude that ABI is the screening test of choice for the diagnosis of patients with PAD due its simplicity, reproducibility and cost effectiveness. Recent studies suggest the use of low ankle pressure ABI as the method for calculating the ABI due to its better sensitivity. Use of ABI is recommended as part of management of patients who have undergone lower extremity revascularization procedures.

As surrogate marker for atherosclerosis, ABI has been found to give very important prognostic information regarding future cardiovascular events. We notice different methods and cutoff points for abnormal ABI have been used in different epidemiologic studies. There is a need for a uniform method of ABI to be used in studies. Current evidence suggests the use of ABI for identifying high risk patients for future cardiovascular and cerebrovascular mortality. In doing so, one can aggressively modify risk factors to prevent both short and long term events.

ACKNOWLEDGMENTS

The authors thank Ms Anum Niazi for helping us review and edit the presentation of the paper.

REFERENCES

[1] Marso SP, Hiatt WR. Peripheral Arterial Disease in Patients with Diabetes. J Am Coll Cardiol 2006; 47: 921-29.
[2] Weitz JI, Byrne J, Craggett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation 1996; 94: 3026-49.
[3] Selvin E, Erlinger T. Prevalence of and risk factors for peripheral arterial disease in the United States, results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-43.
[4] Criqui MH. Peripheral Arterial Disease- Epidemiological Aspects. Vascular Med 2001; 6(Suppl 1): 3-7.
[5] McDermott MM, Criqui MH, Liu k, et al. Lower Ankle / brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. J Vasc Surg 2000; 32: 1164-71.
[6] Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) J Am Coll Cardiol 2006; 47: e1-192.
[7] Bernstein EF, Fronck A. Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 1982; 62: 473-87.
[8] Winsor T. Influence of arterial disease on the systolic pressure blood pressure gradients of the extremity. Am J Med Sci 1950; 220: 117-26.
[9] Criqui MH, Langer RD, Fronck A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Eng J Med 1992; 326: 381-86.
[10] Paris BE, Libow LS, Halperin JL, Mulvihill MN. The prevalence and one-year outcome of limb arterial obstructive disease in a nursing home population. J Am Geriatr Soc 1988; 36: 607-12.
[11] McDermott MM, Liu k,Criqui MH, et al. Ankle-brachial index and subclinical cardiac and carotid disease. The multi-ethnic study of atherosclerosis. Am J Epidemiol 2005; 162: 33-41.
[12] Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105.
[13] McDermott MM, Ferucci L, Simoniek EM, et al. The ankle-brachial index and change in lower extremity functioning over time: the Women’s Health and Aging Study. J Am Geriat Soc 2002; 50: 238-46.
[14] Diehm C, Kareem S, Diehm N, Jansen T, Lawall H. Does calculation of ankle brachial pressure index need revision? Vasa 2005; 34: 123-26.
[15] Murabit JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW, Framingham Study. The ankle-brachial index in the elderly and risk of stroke, coronary disease and death. Arch Intern Med 2003; 63: 1998-42.
[16] Vogt MT, Mckenna M, Anderson SJ, Wolfson SK, Muller LH. The relationship between ankle-arm index and mortality in older men and women. J Am Geriat Soc 1993; 41: 523-30.
[17] Vogt MT, Cauley JA, Newman AB, Muller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-69.
[18] Newmann AB, Shenanski L, Manolillo TA, et al. Ankle- arm index as a predictor of cardiovascular and mortality in the Cardiovascular Health Study Arterioscler Thromb Vasc Bio 1999; 19: 538-45.
[19] Hiatt WR. Medical Treatment of peripheral arterial disease and claudication. N Eng J Med 2001; 344: 1608-21.
[20] Barnes RW. Noninvasive diagnostic assessment of peripheral vascular disease. Circulation 1991; 83(Suppl I): I20-7.
[21] Criqui MH, Deneberg JO, Bird CE, Fronck A, Klauber MR. Langer RD.The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med 1996; 1: 65-71.
[22] McDermott MM, Liu k,Guralnik JM, et al. The ankle brachial index independently predicts walking velocity and walking endurance in Peripheral Arterial Disease. J Am Geriatr Soc 1998; 46: 1355-62.
[23] Sacks D, Bakal CW, Beatty PT, et al. Position statement on the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: a consensus statement developed by the standards division of the society of cardiovascular & interventional radiology. J Vasc Interv Radiol 2002; 13: 353.
[24] Ouriel K, Zarins CK. Doppler Ankle pressure. An evaluation of three methods of expression. Arch Surg 1982; 117: 1297-1300.
[25] Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
[26] Dormundy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter Society Consensus (TASC). J Vase Surg 2000; 31(1pt 2): S1-S56.
[27] Schroder F, Diehm N, Kareem S, et al. A modified method of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. J Vasc Surg 2006 Sep; 44(3): 532-36.
[28] Niazi K, Khan TH, Easley KA. Diagnostic Utility of the two methods of ankle brachial index in the detection of the peripheral arterial disease of lower extremities. Catheter Cardiovasc Interv 2006 Nov; 68(5): 788-92.
[29] Feigelson HS, Criqui MH, Fronck A, Langer RD, Molgaard CA. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of non-invasive tests in a defined population. Am J Epidemiol 1994; 140: 526-34.
[30] Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Bio1996; 22: 391-98.
[31] Stoffers HE, Kester AD, Kaiser V, Rinkens PE, Knottnerus JA. The diagnostic value of the measurement of the ankle- brachial systolic pressure index in primary health care. J Clin Epidemiol 1996; 49: 1401-05.
[32] Carter SA. Indirect systolic pressures and pulse waves in the arterial occlusive disease of the lower extremities. Circulation 1968; 37: 624-37.
[33] Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg 1969; 56: 676-79.
[34] Ouriel K, McDonnell AE, Metz CE, Zarins CK. Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 1982; 91: 686-93.
[35] McLafferty RB, Moneta GL, Taylor LM Jr, Porter JM. Ability of ankle-brachial index to detect lower extremity atherosclerotic disease progression. Arch Surg 1997; 132: 836-40.
[36] Decrinis M, Doder S, Stark G, Pilger E. A prospective evaluation of specificity and sensitivity of the ankle/brachial index in the follow-up of superficial femoral artery occlusions treated by angioplasty. Clin Invest 1994; 72: 592-97.
[37] Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V. Beyond secondary prevention: Identifying the high risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Writing Group. Circulation 2000; 101: e16-22.
[38] Decrinis M, Doder S, Stark G, Pilger E. A prospective evaluation of specificity and sensitivity of the ankle/brachial index in the follow-up of superficial femoral artery occlusions treated by angioplasty. Clin Invest 1994; 72: 592-97.
[39] Decrinis M, Doder S, Stark G, Pilger E. A prospective evaluation of specificity and sensitivity of the ankle/brachial index in the follow-up of superficial femoral artery occlusions treated by angioplasty. Clin Invest 1994; 72: 592-97.
[40] Decrinis M, Doder S, Stark G, Pilger E. A prospective evaluation of specificity and sensitivity of the ankle/brachial index in the follow-up of superficial femoral artery occlusions treated by angioplasty. Clin Invest 1994; 72: 592-97.
[41] Decrinis M, Doder S, Stark G, Pilger E. A prospective evaluation of specificity and sensitivity of the ankle/brachial index in the follow-up of superficial femoral artery occlusions treated by angioplasty. Clin Invest 1994; 72: 592-97.